MA50395A - Sels de (r)-9-(2,5-difluorophénéthyl)-4-éthyl-2-méthyl-1-oxa-4,9-diazaspiro [5.5]undécan-3-one - Google Patents

Sels de (r)-9-(2,5-difluorophénéthyl)-4-éthyl-2-méthyl-1-oxa-4,9-diazaspiro [5.5]undécan-3-one

Info

Publication number: MA50395A
Authority: MA; Morocco
Prior art keywords: difluorophenethyl; undecan; diazaspiro; oxa; salts
Prior art date: 2017-10-17

Application number

MA050395A

Other languages

English (en)

Inventor

Carmen Almansa-Rosales

Nicolas Tesson

Original Assignee

Esteve Pharmaceuticals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-17

Filing date

2018-10-16

Publication date

2020-08-26

2018-10-16 Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa

2020-08-26 Publication of MA50395A publication Critical patent/MA50395A/fr

Links

KALIKXMQWFLZKB-CQSZACIVSA-N (2R)-9-[2-(2,5-difluorophenyl)ethyl]-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one Chemical class FC1=C(CCN2CCC3(CN(C([C@H](O3)C)=O)CC)CC2)C=C(C=C1)F KALIKXMQWFLZKB-CQSZACIVSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

MA050395A 2017-10-17 2018-10-16 Sels de (r)-9-(2,5-difluorophénéthyl)-4-éthyl-2-méthyl-1-oxa-4,9-diazaspiro [5.5]undécan-3-one MA50395A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP17382695		2017-10-17

Publications (1)

Publication Number	Publication Date
MA50395A true MA50395A (fr)	2020-08-26

Family

ID=60201976

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050395A MA50395A (fr)	2017-10-17	2018-10-16	Sels de (r)-9-(2,5-difluorophénéthyl)-4-éthyl-2-méthyl-1-oxa-4,9-diazaspiro [5.5]undécan-3-one

Country Status (26)

Country	Link
US (1)	US11236110B2 (fr)
EP (1)	EP3697795B1 (fr)
JP (1)	JP2020537648A (fr)
KR (1)	KR20200071107A (fr)
CN (1)	CN111263764A (fr)
AR (1)	AR113770A1 (fr)
AU (1)	AU2018353107B2 (fr)
BR (1)	BR112020007359A2 (fr)
CA (1)	CA3076765A1 (fr)
CO (1)	CO2020005710A2 (fr)
DK (1)	DK3697795T3 (fr)
ES (1)	ES2974331T3 (fr)
FI (1)	FI3697795T3 (fr)
IL (1)	IL273751B2 (fr)
LT (1)	LT3697795T (fr)
MA (1)	MA50395A (fr)
MX (1)	MX2020004214A (fr)
MY (1)	MY200894A (fr)
PH (1)	PH12020550104A1 (fr)
PT (1)	PT3697795T (fr)
RU (1)	RU2020115274A (fr)
SG (1)	SG11202002731YA (fr)
SI (1)	SI3697795T1 (fr)
TW (1)	TWI835755B (fr)
WO (1)	WO2019076475A1 (fr)
ZA (1)	ZA202002202B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2021018824A1 (fr) *	2019-07-31	2021-02-04	Esteve Pharmaceuticals, S.A.	Utilisation de (r)-9-(2,5-difluorophénéthyl)-4-éthyl-2-méthyl-1-oxa-4,9-diazaspiro[5,5]undécan-3-one pour le traitement de la douleur nociceptive, de la douleur neuropathique, de la douleur arthritique et de la douleur cancéreuse, tout en ayant des effets secondaires réduits par comparaison avec les opioïdes
WO2024105225A1 (fr)	2022-11-18	2024-05-23	Universitat De Barcelona	Combinaisons synergiques d'un antagoniste du récepteur sigma 1 (s1r) et d'un inhibiteur d'époxyde hydrolase soluble (sehi) et leur utilisation dans le traitement de la douleur

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4332804A (en)	1981-03-23	1982-06-01	Syntex (U.S.A.) Inc.	9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en)	1981-10-19	1982-10-12	Syntex (U.S.A.) Inc.	9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US6114541A (en)	1997-03-10	2000-09-05	Hoffmann-La Roche Inc.	Method for the preparation of α-Bromo-Lactam derivatives
DE102005030051A1 (de)	2005-06-27	2006-12-28	Grünenthal GmbH	Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
PT1961744E (pt)	2005-11-18	2013-05-15	Ono Pharmaceutical Co	Composto que contém um grupo básico e sua utilização
CN101622241B (zh)	2007-03-01	2013-05-22	田边三菱制药株式会社	苯并咪唑化合物及其医药用途
EP1982714A1 (fr)	2007-04-16	2008-10-22	Laboratorios del Dr. Esteve S.A.	Pyrano-pyrazole-aminés
EP2020414A1 (fr)	2007-06-20	2009-02-04	Laboratorios del Dr. Esteve S.A.	Derivés spiro[piperidine-4,4'-thieno[3,2-c]pyran] et composés similaires en tant que inhibiteurs du recepteur sigma pour le traitement de pyschose
EP2197876A1 (fr)	2007-08-29	2010-06-23	Glaxosmithkline LLC	Inhibiteurs de kinase à base de thiazole et d'oxazole
CN102083839B (zh)	2008-02-06	2014-03-26	阿斯利康(瑞典)有限公司	化合物
US8828996B2 (en)	2011-03-14	2014-09-09	Vertex Pharmaceuticals Incorporated	Morpholine-spirocyclic piperidine amides as modulators of ion channels
GB201107985D0 (en)	2011-05-13	2011-06-29	Astrazeneca Ab	Process
CA2909924A1 (fr) *	2013-04-23	2014-10-30	Laboratorios Del Dr. Esteve, S.A.	Composes pyrazino[1,2-a]indole, leur preparation et utilisation dans des medicaments
US9751881B2 (en)	2013-07-31	2017-09-05	Merck Sharp & Dohme Corp.	Inhibitors of the renal outer medullary potassium channel
JP2017100951A (ja) *	2014-04-04	2017-06-08	大正製薬株式会社	オキサゾリジノン及びオキサジナノン誘導体
TWI685497B (zh) *	2014-06-02	2020-02-21	西班牙商伊史帝夫製藥公司	具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物
TW201615643A (zh) *	2014-06-02	2016-05-01	伊史帝夫博士實驗室股份有限公司	具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
TW201615642A (zh)	2014-06-02	2016-05-01	伊史帝夫博士實驗室股份有限公司	具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物

2018
- 2018-10-16 FI FIEP18796360.8T patent/FI3697795T3/fi active
- 2018-10-16 KR KR1020207013907A patent/KR20200071107A/ko not_active Ceased
- 2018-10-16 AR ARP180102999A patent/AR113770A1/es unknown
- 2018-10-16 EP EP18796360.8A patent/EP3697795B1/fr active Active
- 2018-10-16 TW TW107136281A patent/TWI835755B/zh not_active IP Right Cessation
- 2018-10-16 DK DK18796360.8T patent/DK3697795T3/da active
- 2018-10-16 PT PT187963608T patent/PT3697795T/pt unknown
- 2018-10-16 US US16/649,824 patent/US11236110B2/en not_active Expired - Fee Related
- 2018-10-16 MA MA050395A patent/MA50395A/fr unknown
- 2018-10-16 WO PCT/EP2018/000470 patent/WO2019076475A1/fr not_active Ceased
- 2018-10-16 IL IL273751A patent/IL273751B2/en unknown
- 2018-10-16 ES ES18796360T patent/ES2974331T3/es active Active
- 2018-10-16 SG SG11202002731YA patent/SG11202002731YA/en unknown
- 2018-10-16 CN CN201880069276.1A patent/CN111263764A/zh active Pending
- 2018-10-16 LT LTEPPCT/EP2018/000470T patent/LT3697795T/lt unknown
- 2018-10-16 MY MYPI2020001580A patent/MY200894A/en unknown
- 2018-10-16 CA CA3076765A patent/CA3076765A1/fr active Pending
- 2018-10-16 JP JP2020520801A patent/JP2020537648A/ja active Pending
- 2018-10-16 SI SI201831070T patent/SI3697795T1/sl unknown
- 2018-10-16 BR BR112020007359-8A patent/BR112020007359A2/pt unknown
- 2018-10-16 AU AU2018353107A patent/AU2018353107B2/en not_active Ceased
- 2018-10-16 MX MX2020004214A patent/MX2020004214A/es unknown
- 2018-10-16 RU RU2020115274A patent/RU2020115274A/ru unknown
2020
- 2020-03-20 PH PH12020550104A patent/PH12020550104A1/en unknown
- 2020-05-04 ZA ZA2020/02202A patent/ZA202002202B/en unknown
- 2020-05-09 CO CONC2020/0005710A patent/CO2020005710A2/es unknown

Also Published As

Publication number	Publication date
US11236110B2 (en)	2022-02-01
IL273751B2 (en)	2024-02-01
MY200894A (en)	2024-01-22
BR112020007359A2 (pt)	2020-09-29
AR113770A1 (es)	2020-06-10
AU2018353107A1 (en)	2020-04-23
LT3697795T (lt)	2024-04-10
IL273751A (en)	2020-05-31
US20200331929A1 (en)	2020-10-22
SG11202002731YA (en)	2020-05-28
CO2020005710A2 (es)	2020-05-29
RU2020115274A3 (fr)	2022-04-29
RU2020115274A (ru)	2021-11-01
WO2019076475A1 (fr)	2019-04-25
SI3697795T1 (sl)	2024-05-31
KR20200071107A (ko)	2020-06-18
CN111263764A (zh)	2020-06-09
DK3697795T3 (da)	2024-02-26
CA3076765A1 (fr)	2019-04-25
JP2020537648A (ja)	2020-12-24
FI3697795T3 (fi)	2024-02-23
TWI835755B (zh)	2024-03-21
PH12020550104A1 (en)	2021-01-25
PT3697795T (pt)	2024-02-29
ZA202002202B (en)	2025-04-30
EP3697795A1 (fr)	2020-08-26
ES2974331T3 (es)	2024-06-26
AU2018353107B2 (en)	2023-07-06
TW201922752A (zh)	2019-06-16
MX2020004214A (es)	2020-08-13
EP3697795B1 (fr)	2023-11-22
IL273751B1 (en)	2023-10-01

Publication	Publication Date	Title
DK3762385T3 (da)	2025-05-05	Substituerede 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-oner
DK3846904T3 (da)	2023-08-21	5-morpholin-4-yl-pyrazolo[4,3-b]pyridinderivater
EP3661918A4 (fr)	2021-05-12	Analogues de 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-one
JP2018529501A5 (fr)	2019-01-17
CL2018001502A1 (es)	2018-08-17	Procedimiento para el tratamiento de efluente acuoso.
IL260488B (en)	2021-09-30	History of 8-amino-2-oxo-3,1-diaza-spiro-[5.4]-decane
EP3529914A4 (fr)	2019-12-18	Signal de référence de liaison montante
DK3372671T3 (da)	2022-01-24	Dyrkningsmedium, som omfatter oligopeptider
IL249016B (en)	2020-05-31	Alkyl history of 1-oxa-9,4-diazaspiro-undecane compounds with multimodal analgesic activity
PT3707066T (pt)	2022-07-14	Boia de amarração
CL2018003048S1 (es)	2019-02-22	Herramienta de medición para el cuerpo, prenda de vestir.
EP3652095A4 (fr)	2021-04-14	Transporteur de désempilage
LT3723807T (lt)	2021-12-10	Kombinuoti gydymai, apimantys 1h-pirazolo[4,3-b]piridinų vartojimą
ZA202002202B (en)	2025-04-30	Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
CL2018003051S1 (es)	2019-02-22	Herramienta de medición para el cuerpo, prenda de vestir.
CL2018003053S1 (es)	2019-02-22	Herramienta de medición para el cuerpo, prenda de vestir.
CL2018003049S1 (es)	2019-02-22	Herramienta de medición para el cuerpo, prenda de vestir.
CL2019003598A1 (es)	2020-09-21	Métodos para tratar síntomas de gastroparesia usando velusetrag.
ES1205386Y (es)	2018-05-08	Inserto de tejido de absorcion.
IT201600126419A1 (it)	2018-06-14	Sospensione acquosa per uso agronomico.
GB201910691D0 (en)	2019-09-11	Aqueous Solution
GB201813579D0 (en)	2018-10-03	Aqueous solution
ES1235901Y (es)	2020-06-04	Grupo de presión para abrasímetro.
GB201815628D0 (en)	2018-11-07	Belisha beacon
ES2722574R1 (es)	2019-08-27	Proceso para la preparación de 9beta,10alfa-progesterona (retroprogesterona)